Shaping the future of obesity care

Over the last few years, GLP-1 and next-generation anti-obesity medicines have moved from specialist care into one of the most important global health trends. These treatments can deliver clinically meaningful weight loss – often reaching 20% or more – and the category is expected to grow significantly in the coming years.

A major problem is being solved – and a new support need is emerging.

Modern Obesity Treatments work partly by reducing appetite and calorie intake. Total calorie intake may fall by 16–39%, which is central to weight loss – but it also changes the gut environment. Less food intake, altered nutrient patterns, delayed gastric emptying and common digestive side effects create new needs around gut health, digestive comfort, nutritional resilience and long-term wellbeing.

That is why Azento Health is developing azh-biotics® – a microbiome-based companion platform designed to support people before, during and after their weight-loss journey.

Our ambition is to help shape the next generation of modern obesity care: science-led, gut-health focused, and built around the real needs of patients, consumers and healthcare professionals.

We are open to collaborations with companies, clinics, pharmacies, researchers and healthcare organisations who share this ambition. Whether the opportunity is distribution, product development, research collaboration, clinical projects or companion solutions for Modern Obesity Treatments, we would be happy to connect.

Modern obesity care is evolving. Let’s build the support category together. For health and happiness.